BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31621630)

  • 1. Mepolizumab for the Treatment of Eosinophilic Granulomatosis With Polyangiitis: Our Experience.
    Díaz Campos RM; Prudencio Ribera VC; García Moguel I; Fernández-Rodríguez C; Corral Blanco M; Jarrin Estupiñan ME; Melero Moreno C
    J Investig Allergol Clin Immunol; 2019 Oct; 29(5):384-385. PubMed ID: 31621630
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
    Tsurikisawa N; Oshikata C; Watanabe M; Fukuda N; Yamaguchi T; Kiyohara H; Kaneko T
    Int Arch Allergy Immunol; 2021; 182(8):744-756. PubMed ID: 33887721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endobronchial Lesion in Eosinophilic Granulomatosis with Polyangiitis.
    Chen GL; Wu CH; Perng WC
    Iran J Allergy Asthma Immunol; 2017 Dec; 16(6):561-564. PubMed ID: 29338162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
    Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
    Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients.
    Kitamura N; Hamaguchi M; Nishihara M; Ikumi N; Sugiyama K; Nagasawa Y; Tsuzuki H; Yoshizawa S; Tanikawa Y; Oshima M; Asatani S; Kobayashi H; Takei M
    Allergol Int; 2021 Jan; 70(1):148-149. PubMed ID: 32967778
    [No Abstract]   [Full Text] [Related]  

  • 6. Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
    Son H; Lee WJ; Moon J; Yoon S; Jung KH; Park KI; Lee SK; Chu K
    J Neuroimmunol; 2021 Jun; 355():577551. PubMed ID: 33773378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.
    Raffray L; Guillevin L
    Drugs; 2018 Jun; 78(8):809-821. PubMed ID: 29766394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
    Ennis D; Lee JK; Pagnoux C
    Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions.
    Ushio Y; Wakiya R; Kato M; Kameda T; Nakashima S; Shimada H; Mansour MMF; Sugihara K; Miyashita T; Kadowaki N; Dobashi H
    Mod Rheumatol Case Rep; 2021 Jul; 5(2):327-332. PubMed ID: 33533698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on eosinophilic granulomatosis with polyangiitis.
    Furuta S; Iwamoto T; Nakajima H
    Allergol Int; 2019 Oct; 68(4):430-436. PubMed ID: 31266709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
    Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
    J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of mepolizumab.
    Pauk N
    Vnitr Lek; 2023; 69(5):322-328. PubMed ID: 37827831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis.
    Pradhan RR; Nepal G; Mandal S
    Pulm Med; 2019; 2019():4376380. PubMed ID: 30941214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of therapeutic activity of mepolizumab.
    Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
    Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
    [No Abstract]   [Full Text] [Related]  

  • 15. Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
    Colantuono S; Pellicano C; Leodori G; Cilia F; Francone M; Visentini M
    Allergol Int; 2020 Jul; 69(3):483-484. PubMed ID: 32224025
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
    Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
    Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.
    Pouliquen IJ; Austin D; Steinfeld J; Yancey SW
    Clin Ther; 2021 Jul; 43(7):1278-1280. PubMed ID: 34187697
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiitis.
    Miyata Y; Inoue H; Homma T; Tanaka A; Sagara H
    J Investig Allergol Clin Immunol; 2021 Jul; 31(4):346-348. PubMed ID: 33030432
    [No Abstract]   [Full Text] [Related]  

  • 19. Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma.
    Caminati M; Maule M; Nalin F; Senna G; Lunardi C
    Rheumatology (Oxford); 2021 Feb; 60(2):e59-e60. PubMed ID: 32940680
    [No Abstract]   [Full Text] [Related]  

  • 20. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
    Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
    J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.